BioCentury | Apr 15, 2013
Strategy

IP armamentarium

...same time period, Marina Biotech Inc. has done six deals. Marina (formerly MDRNA Inc. and Nastech Pharmaceutical Co. Inc....
BioCentury | Aug 30, 2010
Company News

Cypress, Marina Biotech deal

...interfering RNA-based therapeutics, said the intranasal formulation of carbetocin was developed by its predecessor company, Nastech Pharmaceutical Co. Inc....
BioCentury | Apr 6, 2009
Company News

Dicerna, MDRNA, City of Hope National Medical Center deal

...in its 4Q08 earnings that it returned its rights to the center's IP. MDRNA (formerly Nastech Pharmaceutical Co. Inc....
BioCentury | Apr 6, 2009
Company News

Par Pharmaceutical, QOL Medical deal

...NASDAQ:QCOR, Union City, Calif.), which had acquired it from MDRNA Inc. (NASDAQ:MRNA, Bothell, Wash.) (formerly Nastech Pharmaceutical Co. Inc....
BioCentury | Feb 9, 2009
Company News

Amylin, MDRNA deal

...MDRNA (formerly Nastech Pharmaceutical Co. Inc. ) received a $1 million milestone payment from Amylin under a 2006 deal...
BioCentury | Aug 11, 2008
Company News

MDRNA metabolic, cancer, inflammation news

...The program targets the apolipoprotein B (APOB) gene. BMO Capital Markets is advising MDRNA (formerly Nastech Pharmaceutical Co. Inc....
BioCentury | Jul 7, 2008
Finance

1H08 warrant coverage

...$2.8 Metabasis (NASDAQ:MBRX) $2.34 $2.32 1% 30% $9.8 MiddleBrook (NASDAQ:MBRK) $2.40 $2.99 -20% 50% $21.0 Nastech...
BioCentury | Jun 16, 2008
Strategy

Nastech slices and dices

...Nastech slices and dices By Aaron Bouchie Senior Writer Nastech Pharmaceutical Co. Inc. had been hoping to take forward...
...to treat rheumatoid arthritis (RA) is in preclinical testing, as are its therapeutics against influenza. Nastech...
...stock closed at $13.99 on Nov. 6, the day before P&G ended the deal, giving Nastech...
BioCentury | Jun 16, 2008
Strategy

MDRNA chronicles

...Nastech. B. 9/26/01 - G. Pohl-Boskamp receives exclusive rights in Europe to develop and market Nastech's...
...1/27/03 - Nastech gains $1.08 (15%) to $8.50 after Pharmacia says it will return to Nastech...
...Nastech exclusive rights to RNAi therapeutics against influenza and other respiratory infections. J. 3/2/06 - Nastech...
BioCentury | Jun 16, 2008
Finance

Ebb & Flow

...B19). Separately, the company, formerly Nastech, said it planned to refocus on RNAi therapeutics (see "Nastech...
Items per page:
1 - 10 of 270
BioCentury | Apr 15, 2013
Strategy

IP armamentarium

...same time period, Marina Biotech Inc. has done six deals. Marina (formerly MDRNA Inc. and Nastech Pharmaceutical Co. Inc....
BioCentury | Aug 30, 2010
Company News

Cypress, Marina Biotech deal

...interfering RNA-based therapeutics, said the intranasal formulation of carbetocin was developed by its predecessor company, Nastech Pharmaceutical Co. Inc....
BioCentury | Apr 6, 2009
Company News

Dicerna, MDRNA, City of Hope National Medical Center deal

...in its 4Q08 earnings that it returned its rights to the center's IP. MDRNA (formerly Nastech Pharmaceutical Co. Inc....
BioCentury | Apr 6, 2009
Company News

Par Pharmaceutical, QOL Medical deal

...NASDAQ:QCOR, Union City, Calif.), which had acquired it from MDRNA Inc. (NASDAQ:MRNA, Bothell, Wash.) (formerly Nastech Pharmaceutical Co. Inc....
BioCentury | Feb 9, 2009
Company News

Amylin, MDRNA deal

...MDRNA (formerly Nastech Pharmaceutical Co. Inc. ) received a $1 million milestone payment from Amylin under a 2006 deal...
BioCentury | Aug 11, 2008
Company News

MDRNA metabolic, cancer, inflammation news

...The program targets the apolipoprotein B (APOB) gene. BMO Capital Markets is advising MDRNA (formerly Nastech Pharmaceutical Co. Inc....
BioCentury | Jul 7, 2008
Finance

1H08 warrant coverage

...$2.8 Metabasis (NASDAQ:MBRX) $2.34 $2.32 1% 30% $9.8 MiddleBrook (NASDAQ:MBRK) $2.40 $2.99 -20% 50% $21.0 Nastech...
BioCentury | Jun 16, 2008
Strategy

Nastech slices and dices

...Nastech slices and dices By Aaron Bouchie Senior Writer Nastech Pharmaceutical Co. Inc. had been hoping to take forward...
...to treat rheumatoid arthritis (RA) is in preclinical testing, as are its therapeutics against influenza. Nastech...
...stock closed at $13.99 on Nov. 6, the day before P&G ended the deal, giving Nastech...
BioCentury | Jun 16, 2008
Strategy

MDRNA chronicles

...Nastech. B. 9/26/01 - G. Pohl-Boskamp receives exclusive rights in Europe to develop and market Nastech's...
...1/27/03 - Nastech gains $1.08 (15%) to $8.50 after Pharmacia says it will return to Nastech...
...Nastech exclusive rights to RNAi therapeutics against influenza and other respiratory infections. J. 3/2/06 - Nastech...
BioCentury | Jun 16, 2008
Finance

Ebb & Flow

...B19). Separately, the company, formerly Nastech, said it planned to refocus on RNAi therapeutics (see "Nastech...
Items per page:
1 - 10 of 270